Pharmaceuticals and Biotech

Owkin Bolsters Senior Team With Experienced Pharma Executives to Expand Platform and Strategic Partnerships

Owkin Bolsters Senior Team With Experienced Pharma Executives to Expand Platform and Strategic Partnerships

Owkin, a startup pioneering Federated Learning and AI technologies for medical research and clinical development, announces two senior hires to boost its platform and expand its strategic life science partnerships.Today, Asif Jan and Sezai Taskin bring the Owkin team an…

New Talent at MedEvoke Brings Greater Opportunity for Providing Medical and Scientific Strategy

New Talent at MedEvoke Brings Greater Opportunity for Providing Medical and Scientific Strategy

As an industry leader in global alignment, MedEvoke is positioned to offer unique, scientifically compelling narratives and digitally oriented solutions to overcome the ever-changing needs of Medical Affairs and Clinical Trials professionals. Today, MedEvoke is excited to announce the addition…

Johns Hopkins OpenSpecimen Adoption Over the Years

Johns Hopkins OpenSpecimen Adoption Over the Years

Current Adoption Status: 67 collection protocols / 40+ active usersPublished 67 peer-reviewed articlesSupported 20 grantsManages 400K specimens for 40K study participants100+K specimens sent to Precision Medicine platform*Reference: 2019 OpenSpecimen JHU Annual ReportThe Johns Hopkins University School of Medicine adopted OpenSpecimen…

Climet Announces Introduction of the CI-97 Microbial Air Sampler With Data Integrity and New Advanced Features

Climet Announces Introduction of the CI-97 Microbial Air Sampler With Data Integrity and New Advanced Features

Climet Instruments Company, a Division of Venturedyne Ltd, (herein 'Climet') the leading manufacturer of high quality cleanroom particle counters and microbial samplers, today announced the introduction of their CI-97 microbial air sampler.Climet Instruments Company is very proud to announce the introduction of the…

EW Healthcare Partners Announces the Acquisition of a Majority Stake in Laboratoires Majorelle

EW Healthcare Partners Announces the Acquisition of a Majority Stake in Laboratoires Majorelle

EW Healthcare Partners ("EW") has acquired a majority stake in Laboratoires Majorelle ("Majorelle") from its Founders to support its growth and European expansion in line with the Founders' strategy.Headquartered in Paris, Majorelle is a French specialty pharma company focused on…

Are Internet Pharmacies as Safe as Brick-and-Mortar Ones?

Are Internet Pharmacies as Safe as Brick-and-Mortar Ones?

Americans have been hearing about forthcoming changes to the pharmaceutical industry that will work to lower the prices for prescription drugs for years now. There's been little in the way of progress there. There are a host of reasons why…

WholisticResearch Acquires Domain of Adherex Technologies Inc.

WholisticResearch Acquires Domain of Adherex Technologies Inc.

WholisticResearch, the fact-finding blog on rare nootropics and peptides, announced today that it had acquired the domain name previously owned by Adherex Technologies Inc. biopharmaceutical company, committed to discover and develop therapeutics for cancer and cognitive improvement.The CEO of WholisticResearch shared, "I…

GEN inCode Announces Major UK Collaboration With Royal Brompton and Harefield Hospitals

GEN inCode Announces Major UK Collaboration With Royal Brompton and Harefield Hospitals

GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and Harefield hospitals ("RB&H"), recently merged with Guy's and St Thomas' NHS Foundation Trust ("GSTT"),…

Valkyrie Group Places Big Bet With Hair Growth Pharmaceutical Firm Aneira Pharma, Inc.

Valkyrie Group Places Big Bet With Hair Growth Pharmaceutical Firm Aneira Pharma, Inc.

Investment and growth firm Valkyrie Group ("Valkyrie") has committed an investment of $25 million into Aneira Pharma, Inc. ("Aneira") to be used toward completion of its clinical trials. Aneira is developing a ground-breaking, prescription-based hair growth product for men and…

Ottobock North America Appoints MedTech Industry Leader Marc C. Lundeberg as CEO & Regional President

Ottobock North America Appoints MedTech Industry Leader Marc C. Lundeberg as CEO & Regional President

Today, Ottobock and its Board of Directors announced the appointment of Marc C. Lundeberg as the new CEO and Regional President of the company's North America operation. Effective February 1, 2021, Marc succeeds Brad Ruhl, who will remain on as…

OPTEL Group on Track for Record Year in Asia-Pacific Pharma Sales

OPTEL Group on Track for Record Year in Asia-Pacific Pharma Sales

Adversity has a way of bringing out the best in people, and that has certainly been the case for the hard-working teams of experts who represent OPTEL GROUP in the Asia-Pacific region.OPTEL, a world leader in pharmaceutical track and trace…

CapsCanada Launches Liquid-Filled Hard Capsule Manufacturing Service in North America

CapsCanada Launches Liquid-Filled Hard Capsule Manufacturing Service in North America

CapsCanada, a Lyfe Group™ company and leader in capsule technology for over three decades, is pleased to announce the launch of a new liquid-filled hard capsule manufacturing service. CapsCanada's objective is to support the entire manufacturing process, from formulation and…

Sci-Engi-Medco Solutions Inc. Announces PLOS Publication of a Novel Mechanism of Action for Its AAAPT Technology Expanding the Therapeutic Index of Difficult to Treat Cancers

Sci-Engi-Medco Solutions Inc. Announces PLOS Publication of a Novel Mechanism of Action for Its AAAPT Technology Expanding the Therapeutic Index of Difficult to Treat Cancers

On this Triple Negative Breast Cancer awareness day, Sci-Engi-Medco Solutions Inc. (SEMCO), a private cancer drug discovery and development company that explores its proprietary small molecule targeted anticancer agent tumor sensitizing technology, announced the publication of new research findings in PLOS…

Akelos Inc.’s Lead Compound Achieves Preclinical Safety  Milestone

Akelos Inc.’s Lead Compound Achieves Preclinical Safety Milestone

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, announces the lead compound AKE-1018 significantly reduces neuropathic pain in preclinical testing.Akelos's oral lead compound AKE-1018, at 10-times the lowest…

Enterin to Present at Chardan’s Virtual 3rd Annual Microbiome Medicines Summit

Enterin to Present at Chardan’s Virtual 3rd Annual Microbiome Medicines Summit

Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative diseases, announces that the company will be presenting at Chardan's virtual 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 8:30 a.m. ET.Dr. Denise Barbut, Enterin's…

RxCelerate Launch Galaxy™: A Next-Generation Antibody Discovery Platform

RxCelerate Launch Galaxy™: A Next-Generation Antibody Discovery Platform

RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Galaxy™, that offers significant advantages over the current generation of tools for delivery of new therapeutic monoclonal antibodies."Monoclonal antibodies make up…

Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

Avexegen Therapeutics Inc. today announced that it has received a Phase 2 award of $2.94 million under the National Institutes of Health's Small Business Innovation Research Program (SBIR) for the development of an oral Neuregulin-4-based therapy for inflammatory bowel disease…

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300

Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Krabbe Disease (a.k.a. Globoid Cell Leukodystrophy) with PLX-300 from the U.S. Food and…

Inova Appoints Claude Basset as Chief Product Officer

Inova Appoints Claude Basset as Chief Product Officer

Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer.  Inova is a French Tech success story that, now in its 10th year, has captured more than half of the partnering…

Peak Serum, Inc. Appoints Interim CEO

Peak Serum, Inc. Appoints Interim CEO

Effectively immediately, Thomas Kutrubes has been removed from privately owned and independent supplier of life science laboratory products — Peak Serum, Inc. (Peak) — by the chief restructuring officer and Trustee, Jay Roderick. Michael Dodge, Peak's current global director of…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login